Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
- 19 April 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 55 (5), 1462-1472
- https://doi.org/10.1002/hep.25509
Abstract
The objective of this nationwide case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs). A total of 606,583 type 2 diabetic patients, age 30 years and above, without a history of cancer were identified from the Taiwan National Health Insurance claims database during the period between January 1 2000 and December 31 2000. As of December 31 2007, patients with incident cancer of liver, colorectal, lung, and urinary bladder were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratio (OR) and 95% confidence interval (CI) between TZDs and cancer incidence. A total of 10,741 liver cancer cases, 7,200 colorectal cancer cases, and 70,559 diabetic controls were included. A significantly lower risk of liver cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively. The protective effects were stronger for higher cumulative dosage and longer duration. For colorectal cancer, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk (OR: 0.86; 95% CI: 0.76-0.96). TZDs were not associated with lung and bladder cancer incidence, although a potential increased risk for bladder cancer with pioglitazone use ≥3 years could not be excluded (OR: 1.56; 95% CI: 0.51-4.74). The use of pioglitazone and rosiglitazone is associated with a decreased liver cancer incidence in diabetic patients. The effects on occurrence of specific cancer types may be different for pioglitazone and rosiglitazone.This publication has 47 references indexed in Scilit:
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathThe New England Journal of Medicine, 2011
- Diabetes and CancerDiabetes Care, 2010
- Epidemiological aspects of neoplasms in diabetesActa Diabetologica, 2010
- Diabetes and cancerEndocrine-Related Cancer, 2009
- A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fishThe Lancet Oncology, 2009
- Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysisThe Lancet Oncology, 2008
- The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth StudyPEDIATRICS, 2006
- American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical ActivityCA: A Cancer Journal for Clinicians, 2006
- Physical Activity and Cancer Prevention???Data from Epidemiologic StudiesMedicine & Science in Sports & Exercise, 2003
- Ligands for Peroxisome Proliferator-Activated Receptor Inhibit Growth and Induce Apoptosis of Human Papillary Thyroid Carcinoma CellsJournal of Clinical Endocrinology & Metabolism, 2001